#CancerStemCells
LightNews LightNews
natcellbio.nature.com
☀️Our June issue is out!
Cover: mechanical polarization

👉Perspective: #RNA in #aging
👉Review: #ExtracellularVesicles
🔬 #hematopoiesis #epigenetics #mechanobiology #morphogens #ferroptosis #LipidDroplets #CellMigration #melanocytes #embryos #CancerStemCells & more!

www.nature.com/ncb/volumes/...
June 19, 2026 at 8:59 AM
atanas-g-atanasov.bsky.social
🧵 4/6
Review highlights CSC targeting—key to preventing relapse & drug resistance.

🌐 #CancerStemCells #OncologyResearch #PrecisionMedicine @kennarubin.bsky.social @science-george.bsky.social @myribw.bsky.social @michaeldonoian.bsky.social @ryuma21.bsky.social @martinbue.bsky.social
September 21, 2025 at 12:28 PM
jesperolsenlab.bsky.social
Our new study is out! 🚨
We used mass spectrometry to uncover a conserved stemness signature in ovarian cancer stem cells (OCSCs).
Check what we found and why it matters. 👇
#OvarianCancer #CancerStemCells #MassSpec #proteomics
www.mcponline.org/article/S153...
Quantitative proteomics and phosphoproteomics analysis of patient-derived ovarian cancer stem cells
High-grade serous ovarian carcinoma (HGSOC) is the deadliest gynecologic cancer. Key to the progression and ultimate lethality of this subtype is the intra-tumoral heterogeneity (ITH), which is define...
www.mcponline.org
April 24, 2025 at 8:57 AM
skodalab.bsky.social
Hi Bluesky! This is us, #ChildhoodCancer #Mitochondria #CancerStemCells #PrecisionMedicine maniacs. First post as we start fresh from scratch 😉 Still missing so many great accounts here, but let’s get things rolling! Excited to share and discover interesting content again. The sky’s the limit! 🚀
January 23, 2025 at 4:31 PM
natcellbio.nature.com
☕Zhao et al. develop a microwell cell-chip-based culture platform enabling high-throughput generation of micro-tumorspheres and enrichment of functional #CancerStemCells from biopsies from patients with #BreastCancer, facilitating personalized drug testing.
👉https://rdcu.be/flpvR
bit.ly/3Rx7AWt
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform - Nature Cell Biology
Zhao et al. develop a microwell cell-chip-based culture platform that enables high-throughput generation of micro-tumourspheres and enrichment of functional cancer stem cells from biopsies obtained fr...
bit.ly
May 29, 2026 at 11:05 AM
genesndiseases.bsky.social
This new review sheds light on the complex relationship between #Ferroptosis and the biology of #CancerStemCells, aiming to develop new ways to eliminate these cells, ultimately improving #Cancer treatment and preventing recurrence. #medsky
#OpenAccess:
doi.org/10.1016/j.ge...
August 27, 2025 at 12:30 AM
chp-pivot.bsky.social
📘 CHP Archive Spotlight #06
Perspective (2024) | Kondo
Targeting cancer stem cell heterogeneity & plasticity with a miRNA-dependent AAV system designed to eradicate diverse CSC populations while minimizing side effects.
🔗 doi.org/10.47248/chp...
#CancerStemCells #Heterogeneity #AAV
Graphical abstract illustrating cancer stem cell (CSC) heterogeneity driven by genetic, epigenetic, and environmental factors, and a proposed miRNA-dependent AAV strategy selectively eradicating heterogeneous CSCs to prevent recurrence.
February 28, 2026 at 4:33 AM
cancerdynamics.bsky.social
🌟 Thanks to Elaine Fuchs from @rockefelleruniv.bsky.social & @hhmi.org for delivering an insightful seminar on “Tissue Stem Cells: Coping With Stress and Cancer,” hosted by @elhamazizi.bsky.social. This one was packed with thought-provoking science. #CancerResearch #CancerStemCells
Elaine Fuchs presenting
May 15, 2025 at 3:01 PM
phoenixmiao1010.bsky.social
Thrilled to share our latest review with
@JudithAgudo1
on the unique immune resistance mechanisms of #CancerStemCells in solid tumors! Explore how these insights are reshaping cancer therapy approaches. #Immunology #CancerResearch #CancerImmunotherapy"
www.nature.com/articles/s41...
Stemness in solid malignancies: coping with immune attack - Nature Reviews Cancer
Immunotherapy shows promise in treating cancers by engineering T cells or using antibodies to activate them. However, cancer stem cells (CSCs) resist immunotherapies and drive cancer relapse. In this ...
www.nature.com
November 14, 2024 at 12:19 AM
sigtrans-sttt.bsky.social
Reviewing the role of #epigenetic alterations on #CancerStemness, with a discussion on the therapeutic strategies targeting epigenetic modifiers to eliminate #CancerStemCells. #medsky @foxchasesurgonc.bsky.social

Read this #STTT #OpenAccess: doi.org/10.1038/s413...
October 4, 2025 at 4:30 PM
sigtrans-sttt.bsky.social
An overview of #CancerStemCells (CSCs), their origins, associated signaling pathways, & their role in #tumorigenesis, with insights into CSC-targeting therapeutic strategies, their limitations, & future directions. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...
October 25, 2025 at 4:30 AM
bvsspa.bsky.social
👉 Disponible en #risalud hdl.handle.net/10668/30228

#BVSSPA #OnychocoloneA #CancerStemCells
September 18, 2026 at 6:12 AM
dreugenemanleyjr.bsky.social
I was recently on the Integrative Cancer Solutions #podcast hosted by Dr. Karlfeldt. We touched on tumor #micronevironment, #cancerstemcells, how women were not involved in biomedical research and what changed it, and lack of diversity in #celllines.
May 25, 2026 at 7:01 PM
scheq.org
Our Founder was on the Integrative Cancer Solutions #podcast hosted by Dr. Karlfeldt. In this episode they touched on:
- Tumor #microenvironment
- #cancerstemcells
- Why women were not involved in biomedical research and what changed it
- Diversity in patient samples.
May 25, 2026 at 7:03 PM
stemcellsciencenews.com
A growing body of evidence has confirmed the critical role of #CancerStemCells in tumor progression, drug resistance, and recurrence, which lays a solid foundation for the development of potential therapeutic targets and intervention strategies. 🎯

Give it a read: https://go.nature.com/4ycVpyN
July 8, 2026 at 9:43 PM
sigtrans-sttt.bsky.social
Could targeting #CancerStemCells improve long-term #Cancer control?

This review in #STTT examines CSC plasticity, therapy resistance, emerging interventions, and clinical challenges while highlighting technologies for advancing translation.

#OpenAccess: doi.org/10.1038/s413...
Translational insights and clinical challenges of targeting cancer stem cells
August 19, 2026 at 2:45 AM
chp-pivot.bsky.social
📘 CHP Archive Spotlight #07
Review (2024) | Her et al.
How do noncoding RNAs drive cancer plasticity?
miRNAs, lncRNAs, circRNAs & tRNA fragments regulate stemness, EMT, epigenetics & therapy resistance — with emerging roles as biomarkers & targets.
🔗 doi.org/10.47248/chp...
#ncRNA #CancerStemCells
Schematic overview of noncoding RNA functions in cancer cell plasticity. The figure is organized by RNA type: miRNAs regulate pluripotency inhibition, translational repression, mRNA degradation, EMT transition, cancer stem cell initiation, and metastasis; lncRNAs modulate epigenetic regulation, transcription, signaling pathways, chromatin architecture, alternative splicing, and dedifferentiation; circRNAs function as miRNA sponges, regulate transcription, interact with RNA-binding proteins, and influence self-renewal and apoptosis; tRNAs and tRNA-derived fragments regulate translation, mRNA stability, mitochondrial homeostasis, metabolic reprogramming, and hormone-dependent signaling. Illustration of therapeutic strategies targeting noncoding RNAs in cancer. Approaches include synthetic miRNA mimics and lentiviral delivery for oncogene suppression, antisense oligonucleotides and RNA sponges for tumor suppressor restoration, CRISPR-based activation or repression of lncRNAs, synthetic circRNA sponges and Cas13-mediated cleavage, siRNA-loaded nanoparticles, and inhibition of tRNA methyltransferases to block translation and tumor growth.
February 28, 2026 at 4:52 AM
alicefrolov.bsky.social
Sharing a new data visualization from our ongoing work on clonal dynamics in therapy-resistant malignancies.

#CancerStemCells #ClonalEvolution #TumorHeterogeneity #TherapyResistance #MinimalResidualDisease #CancerModeling #TumorPlasticity #SingleCellGenomics
Sharing a new data visualization from our ongoing work on clonal dynamics in therapy-resistant malignancies. Figure title: "Subclonal expansion and cancer stem cell enrichment across therapy phases" Subtitle: "Simulated clonal trajectories: therapy-resistant subclones expand as CSC fraction rises through relapse" The visualization employs a clonal fan slopegraph, in which branching subclone trajectories are tracked across four discrete treatment phases (diagnosis, induction response, minimal residual disease, and relapse). Each terminal branch corresponds to a genetically distinct subclone, with vertical position encoding its relative population frequency and branch width scaled to absolute clone size. Superimposed CSC-fraction ribbons quantify the proportion of cells within each subclone bearing a cancer stem cell (CSC) phenotype, operationally defined here by a composite stemness signature. I want to emphasize that the underlying data are simulated. The trajectories are generated from a stochastic branching model parameterized to reproduce a well-documented, literature-grounded trend rather than to represent a specific empirical cohort. The intent is illustrative and hypothesis-clarifying. The central pattern is instructive. Under cytotoxic pressure, dominant treatment-sensitive subclones contract sharply during induction, producing an apparent response, while minor subclones harboring resistance-conferring lesions persist through the MRD bottleneck. Critically, these persistent subclones exhibit disproportionately elevated CSC fractions, consistent with the notion that quiescent, stemness-associated states underwrite drug tolerance and subsequent regrowth. During relapse, the resistant subclones undergo expansion, and the population-level CSC fraction rises accordingly, reflecting both selection and plasticity-driven state transitions.
August 27, 2026 at 5:00 PM
genesndiseases.bsky.social
This review details the role of #ubiquitination molecules, E3 Ub ligases, #deubiquitinases, & transcription factors in regulating #CancerStemCells (CSC) and describe how the Ub-proteasome system modulates the signaling pathways governing CSC maintenance. #medsky

#OpenAccess:
Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality
March 10, 2025 at 2:30 PM
genesndiseases.bsky.social
This review details how various cellular & soluble components in the #TumorMicroenvironment support the maintenance & function of #CancerStemCells (CSCs), and discusses the therapeutic implications of targeting this synergistic interplay. #CancerImmunotherapy #medsky

#OpenAccess: buff.ly/YrZeEzS
Tumor microenvironment of cancer stem cells: Perspectives on cancer stem cell targeting
May 17, 2025 at 4:15 PM
genesndiseases.bsky.social
The SLC27A5/PABPC1 axis induces #AlternativePolyadenylation (APA) of the METTL14-3’UTR, resulting in shorter 3’UTR METTL14 isoforms that evade miRNA-mediated suppression, thereby inhibiting #CancerStemCells in #HepatocellularCarcinoma. #medsky

#OpenAccess: www.sciencedirect.com/science/arti...
SLC27A5 inhibits cancer stem cells by inducing alternative polyadenylation of METTL14 in hepatocellular carcinoma
May 8, 2025 at 12:01 AM
bionewscentral.com
A novel #immunotherapy employs a #nanovaccine that targets both bulk #TumorCells and #CancerStemCells to reduce the risk of post‑surgical #recurrence and #metastasis.
#CancerImmunotherapy #CancerVaccine
Novel nanovaccine halts tumor growth and reduces cancer recurrence – BioNews Central
A novel immunotherapy employs a nanovaccine that targets both bulk tumor cells and cancer stem cells to reduce the risk of post‑surgical recurrence and metastasis. ...
sbee.link
September 25, 2025 at 2:46 AM
chp-pivot.bsky.social
📘 CHP Archive Spotlight #05
Perspective (2024) | Jamroze, Liu & Tang
AR signaling inhibitors induce lineage plasticity in prostate cancer, promoting stem-like, mesenchymal & neural states driving CRPC & NEPC progression.
🔗 doi.org/10.47248/chp...
#LineagePlasticity #CRPC #CancerStemCells
Graphical abstract illustrating ARSI-induced lineage plasticity in prostate cancer. Androgen receptor signaling inhibition promotes transition from prostate adenocarcinoma (PRAD) to aggressive CRPC variants with increased mesenchymal, basal, stem-like, and neural cell states, highlighting reversibility and tumor heterogeneity.
February 27, 2026 at 2:32 AM
alicefrolov.bsky.social
Sharing a visualization from ongoing work on cancer stem cell (CSC) clonal dynamics under therapeutic pressure.

#CancerStemCells #TumorHeterogeneity #ClonalEvolution #MinimalResidualDisease #TumorPlasticity #DrugTolerantPersisters #SingleCellGenomics #PhylogeneticReconstruction
Sharing a visualization from ongoing work on cancer stem cell (CSC) clonal dynamics under therapeutic pressure. Figure: "Therapy reshapes clonal hierarchy via stem-like subclone selection" Subtitle: "Ranked clonal fraction of tumor subclones across treatment phases; stem-marked clones rise under selective pressure" The chart is a phylogenetic bump plot (Muller-style ranked clonal flow) tracking the relative clonal fraction of individual subclones across sequential treatment phases: baseline, on-treatment, minimal residual disease (MRD), and relapse. Each ribbon corresponds to a distinct subclone, with vertical band thickness encoding clonal fraction and vertical ordering encoding rank. Subclones carrying stem-associated marker states (e.g., high ALDH activity, CD133/CD44 enrichment, quiescence-linked transcriptional programs) are highlighted to distinguish them from bulk proliferative lineages. The illustrated trajectory recapitulates a well-documented pattern: cytotoxic selection preferentially depletes proliferative, differentiation-committed subclones while sparing slow-cycling, stem-marked populations. During the MRD window, stem-like ribbons ascend in rank despite overall tumor contraction, consistent with therapy-tolerant persister states buffered by quiescence, enhanced drug efflux, and reinforced self-renewal signaling (WNT, NOTCH, Hedgehog). At relapse, these ascended subclones seed the reconstituted hierarchy, producing a repopulated tumor with an altered clonal architecture rather than a faithful reconstruction of the baseline composition. I want to emphasize that the underlying data here are simulated. The intent is to render a literature-grounded trend in an interpretable topological format, not to present empirical measurements. The parameterization draws on reported CSC plasticity and selection dynamics, but ribbon values are synthetic.
September 10, 2026 at 5:07 PM
wayne002.bsky.social
Review of PRX5 in cancer stem cells

📊 Low ROS sustain CSC self-renewal, drug resistance.
🔬 PRX5 redox balance protects STAT3 from inactivation.
💡 Target: destabilize STAT3, reduce CSC self-renewal.
DOI: https://doi.org/10.32604/biocell.2026.079386 #CancerStemCells #PRX5 #STAT3
Schematic representation of the human PRX family, highlighting isoform classification, catalytic mechanisms, and subcellular localization. Mammalian PRXs are categorized into typical 2-Cys (PRX1–4), atypical 2-Cys (PRX5), and 1-Cys (PRX6) subgroups based on the number and positioning of catalytic cysteine residues. Unlike typical 2-Cys PRXs, which form intermolecular disulfide bonds, PRX5 utilizes an intramolecular disulfide bond, conferring distinct structural and functional properties. Abbreviations: SO 2 H, sulfinic acid (hyperoxidized inactive form); MTS, mitochondrial targeting sequence; PTS1, peroxisomal targeting signal 1 ( Fig. 1 is our original work and was prepared using Microsoft PowerPoint 2021).
September 16, 2026 at 8:04 AM